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ABSTRACT
Mammary development is a continuous and cyclic process that is under tight
regulatory control from hormones and cell cycle regulators to mediate transition
from the various proliferative, differential and apoptotic steps. Puberty is a timepoint of high proliferation during development that has higher susceptibility to
breast cancer. Spy1 is a cyclin-like protein known to regulate mammary
development and increase proliferation with previous work also showing Spy1
increases tumor susceptibility and pubertal lateral side branching. In this work we
demonstrate that elevated levels of Spy1 in puberty significantly increase the
number of lateral branches and total epithelial content in mice. Similarly, the
pubertal glands saw increased levels of amphiregulin and proliferation.
Furthermore, it was demonstrated that elevated Spy1 levels can increase budding
in HC11 3D culture and increase total size in primary cell organoids. This data
revealed the unique ability of Spy1 to manipulate developmental pathways in the
mammary gland.
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Introduction

The Mammary Gland
The mammary gland is a secretory exocrine organ that follows a complex developmental history
which leads to the eventual production of milk (Watson and Khaled, 2008). The term mammal
comes from the Latin “mammas” or breast as all mammals possess mammary glands. The
mammary gland is a functional organ exclusive to higher vertebrates which plays a key role in
offspring development and survival and plays an important role in the life history of humans
(Oftedal, 2002). The development of the mammary gland is also linked to prevailing illnesses
associated with the organ such as cancer (Nwabo Kamdje et al., 2017)
Most of mammary development occurs postnatally, which allows for genetic manipulation
without the fear of consequences to other organs systems. Organ systems that develop in
embryogenesis are often controlled by master regulatory genes that, when manipulated, can have
effects on other organs or simply be lethal to the embryo. Therefore the mammary gland is an
ideal study system. (Hens and Wysolmerski, 2005; Richert et al., 2000). Development of the postembryonic mammary gland is characterized by epithelial invasion into the rudimentary fat-pad
via ductal elongation until the ducts reach the end of the fat pad (Hinck and Silberstein, 2005).
During puberty and progression into the adult gland there is an increase in secondary and tertiary
side branching off previously formed ducts. During pregnancy, changes to the systemic hormone
profile, such as an increase in estrogen and progesterone, have dramatic effects on the mammary
gland (Vonderhaar and Greco, 1979). In this phase the mammary gland undergoes a spike in
proliferation and a loss in adipocyte content; these changes allow for the eventual filling of the
mammary gland and differentiation to produce alveoli. During lactation the mammary alveoli, the
functional units of the gland which contain milk-producing cells and contractile cells, produce and
distribute milk to the ducts as well as to the nipple (Watson and Khaled, 2008). Finally, following
weaning, the mammary gland undergoes involution, an apoptotic period that returns the
differentiated mammary gland to its resting state of development (Watson, 2006a).
As a model, the mouse mammary gland bears meaningful similarities to the human mammary
gland in both structure, cellular composition, and development as well as cancer initiation
1

(Parmar and Cunha, 2004). The similarity of mouse mammary gland histology to human cancers
is among the many reasons it serves as a viable model (Cardiff and Wellings, 1999). However,
there are differences in morphology between the two species such as the epithelial functional
units that extend the mammary gland. In mice stem cell rich structures called terminal end buds
(TEBs) elongate the ductal structures further into the fat-pad. Conversely, the human ductal
elongation is much more complex with 17-30 separate lobes connected to the nipple and formed
through side branching of a primary duct. The functional unit of the human mammary gland is the
terminal ductal lobular unit (TDLU) which bears similarities to TEBs in mice but whose cellular
composition is not as well understood. Differences in the fat-pads of the two species include
higher adipose cell content in the mouse, while the human fat-pad contains specialized stroma
surrounding the TLDU’s and rich in enzyme secreting fibroblasts (Dontu and Ince, 2015). Other
differences include higher levels of involution in mouse versus human gland, and significantly
lower baseline levels of estrogen in the mouse (Dontu and Ince, 2015). While it is important to
highlight these differences when drawing comparisons, these discrepancies are outweighed by
the similarities in the glands and utility of the mouse. Finally, the ability to manipulate gene
expression that lead to different phenotypes and tumor susceptibility make the mouse mammary
gland an ideal system to study developmental effects and tumor formation. (Hens and
Wysolmerski, 2005).

Mouse Mammary Development in Embryogenesis and Puberty
Embryonic mammary gland development in the mouse begins during mid-gestation at embryonic
day 10.5 (Cowin and Wysolmerski, 2010) where mammary lines form from the hindleg to the
forelimb. At day 11.5, ectodermal cells situated on these mammary lines will migrate to 5 specific
locations and aggregate to form a multilayered and column like placode (Cowin and Wysolmerski,
2010; Watson and Khaled, 2008). The cells within these mammary placodes differentiate to
epithelial cells which are now distinct from their environment. Following this, at embryonic day
12.5 the mammary placodes become visible raised buds that begin invading downward into the
dermal mesenchyme. At embryonic day 13.5 the buds invaginate entirely into the underlying
mesenchyme to form the mammary buds (Brisken and O’Malley, 2010; Richert et al., 2000). The
mesenchymal cells around the invaginated buds aggregate and form the mammary mesenchyme
2

(Richert et al., 2000; Watson and Khaled, 2008). During embryonic day 15 to 16 the mammary
buds invade into the fat pad precursor and form a rudimentary ductal structure. Ductal
development and branching are arrested at embryonic day 18.5 until estrogen-driven pubertal
development occurs (Richert et al., 2000). In contrast to embryonic development, which is
hormone-independent, growth during puberty occurs in a hormone-dependent manner (Brisken
and O’Malley, 2010). At the onset of puberty, rapid, estrogen-driven proliferation and elongation
of the duct drives development further into the mammary fat pad. Estrogen-driven growth leads
to elongation of the rudimentary ductal tree until the leading edge of the duct reaches the end of
the fat-pad. Ductal elongation is facilitated by the formation of terminal end buds or TEBs (Hinck
and Silberstein, 2005; Richert et al., 2000) which invade and grow into the fat-pad. Terminal end
buds are proliferative structures at the ends of the ducts which are formed by pluripotent stemlike cap cells that can divide rapidly and differentiate to the multitude of mammary cells known
to constitute the gland. Cap cells that divide asymmetrically can differentiate into myoepithelial
cells, which will line the outside of the elongating duct maintaining a direct connection to the
surrounding stroma, or luminal epithelial cells which line the inside of the developing duct
(Anderson et al., 2007; Richert et al., 2000; Watson and Khaled, 2008). Beneath the cap cells lie a
multitude of dividing epithelial cells needed to move the gland forward by maintaining the
structure of the developing duct. These epithelial cells will eventually undergo apoptosis and be
degraded by macrophages to allow for hollowing of the duct, a process necessary for future
differentiation and milk production (Brisken and O’Malley, 2010; Nelson et al., 2006; Richert et
al., 2000). As TEBs invade into the fat-pad to extend the length of the developing duct, they bifurcate to produce new ductal branches of the primary line (Anderson et al., 2007; Hinck and
Silberstein, 2005). Bifurcation is a well-regulated process and under the control of remodeling
matrix metallo-proteases (MMPs) (Anderson et al., 2007). Once the TEBs reach the end of the
fat-pad, around 8 to 12 weeks, they atrophy and become terminal ducts. A schematic of mammary
development to the adult virgin can be seen in Figure 1. Estrogen and progesterone driven growth
of side branches will continue in cycles unless pregnancy occurs.
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Figure 1. Overview of mammary development. A) Mammary development from birth to adult
virgin. Embryonic mammary development leads to a rudimentary mammary tree which remains
quiescent in the fat-pad until puberty. Pubertal increase in estrogen gives rise to TEBs at the ends
of major ducts which proliferate and extend the mammary ductal tree towards the ends of the
fat-pad. As the ducts extend unidirectionally, lateral branching works to fill the fat-pad in a
multidirectional way and add unique patterning. This process continues until the mouse reaches
adulthood or until pregnancy. During pregnancy estrogen and progesterone increase and tissue
remodeling leads to alveoli formation for milk production. Lactation in the mouse mammary gland
functions through alveolar epithelial cells producing milk and surrounding myoepithelial cells
contracting and pushing it through the ducts back to the nipple. Once suckling stimuli are removed
the gland is apoptotic-ally remodeled in involution back to the adult gland structure. B) Cell
morphology of terminal end buds (TEBs) and lactating alveoli respectively. Figure adapted from
(Inman et al., 2015).
4

Branching Morphogenesis and Lateral Branching

Branching morphogenesis is a process by which organ systems grow and develop the unique and
functional properties of their architecture (Iber and Menshykau, 2013). It is a complex process by
which a ductal network expands, filling the mesenchyme pad multi-directionally. Branching can
occur in four major directional process: lateral branching, trilobed bifurcation, planar bifurcation
and finally orthogonal bifurcation (Iber and Menshykau, 2013). A schematic of the four branching
types can be seen in Figure 2. In many organ systems, the interplay between fibroblast growth
factor 10 (FGF10) and sonic hedgehog (SHH) signaling is a key initiator and directional driver of
bifurcation and branching. In the mouse lung, for example, the presence of FGF10 in the
mesenchyme activates the fibroblast growth factor receptor (FGFR) in the local epithelial cells and
upregulates proliferation while activating SHH signal (Bellusci et al., 1997). However, the salivary
gland uses the same mesenchyme FGF10 epithelial receptor interplay but leads to SHH inhibition
because the SHH-receptor complex acts in an inhibitory fashion in this organ system (Bellusci et
al., 1997; Makarenkova et al., 2009). For a branching organ to achieve full arborization it requires
symmetry-breaking events. These events are vital because simple tissue outgrowth will lead to
rotational symmetry in the developing organ which cannot fully exploit the surrounding
mesenchyme. As branching events extend epithelial tissue into the mesenchyme, they add an
instability and unique patterning to the otherwise symmetrical outgrowth (Ochoa-Espinosa and
Affolter, 2012) Symmetry breaking in a biological system is linked to increasing complexity and
diversification which can give rise to specialized cellular structures with unique differentiation
trajectories. In epithelial glandular cells, apical-basal polarity introduces a break in cellular
symmetry that leads to two distinct epithelial surfaces – basal and often, luminal (Nelson, 2009).
When this apical asymmetry is extended to whole tissues it gives rise to distinct organ functions.
Other models have been explored to describe branching systems and the patterns they create.
The mechanical branching model has been proposed to describe phenomena observed in tissue
recombination systems; which used lung mesenchyme transplanted with ureteric epithelial buds
leading to lung specific patterned growth in the kidney epithelium (Lin et al., 2001). The proposed
mechanical model is based on differences in viscosity between the epithelium and mesenchyme
where a process known as “viscous fingering” would produce branches from an expanding
epithelium. While the authors admit the proposed model does not account for many aspects of
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branching, together with signaling pathways and extra-cellular matrix inhibitory networks, the
model could indeed play a role (Iber and Menshykau, 2013).
Interestingly, Hannezo et al proposed a unified model for branching morphogenesis that could
account for the expansion of the mammary gland and branching using a simple mathematical rule
set (Hannezo et al., 2017). The simulated model functioned on two major rules. The first rule is
that an expanding duct can randomly choose between continuing to grow or bifurcating into two
new units. The second rule was when an active tip reaches an already expanded duct it will
terminate its growth and the branch will end. They demonstrated that this system alone, when
limited to a simulated fat-pad, could effectively match the size and complexity of an adult mouse
mammary ductal tree (Hannezo et al., 2017). Branching morphogenesis therefore likely involves
several mechanisms including differences in signaling cascades, interplay between the
mesenchyme and epithelium and inhibition based of proximity to growing and expanding ducts.
In the mouse mammary gland, ductal elongation and planar bifurcation are two of the main
processes occurring during puberty that allow for expansion of the ductal tree. Lateral branching
is a separate process that allows for further expansion of the ductal tree to fill the remainder of
the fat pad. Initiation of lateral branch points occurs when increased proliferation at a specific
point of the duct forms a mammary bud. Several paracrine and exocrine growth factors can
elongate the mammary bud on their own once initiation has occurred (Moses and Barcellos-Hoff,
2011; Nelson et al., 2006). At specific locations along the developing mammary duct a decrease
in Transforming Growth Factor-β (TGF-β), and an increase in levels of Fibroblast Growth Factor 2
(FGF2) and FGF10 as well as paracrine release of Epithelial Growth Factor (EGF) lead to formation
of buds and subsequent formation of lateral branches, suggesting a similar feedback loop as the
FGF10-FGFR SHH signaling pathway in other branching systems (Moses and Barcellos-Hoff, 2011;
Nelson et al., 2006; Richert et al., 2000). TGF-β activation inhibits the formation of lateral branches
throughout the duct. All cells are known to secrete LTGF- β, a TGF-β-1,3 precursor molecule, which
can then be activated by a series of enzymes including matrix metallo-proteases (MMP) and
integrins (Moses and Barcellos-Hoff, 2011). When activated, TGF-β and its accompanying receptor
act as an inhibitory complex that is maintained at high levels in the developing duct. This
consistent activation is needed to keep the duct from over-proliferating as it expands (Wakefield
et al., 2001). When TGF- β-receptor I and II dimerize from TGF-β-1/3 signaling it leads to a cascade
of events which activate Wnt5A, p16, p27 and finally the tumor suppressor p53. These factors
6

work to arrest the cell cycle through Cip/Kip family activation; which functions through p53
activation and inhibition of C-Myc, a regulator and proto-oncogene, that further inhibits
proliferation (Aupperlee et al., 2013; Moses and Barcellos-Hoff, 2011). Forrester et al 2005 have
also shown that mammary development can become hyperplastic and abnormal when TGF-β is
knocked out, demonstrating its regulatory capacity in the developing duct (Forrester et al., 2005).
Similarly, TGF- β-1 and TGF- β-3 were shown to have important and complex roles in several stages
of mammary development by acting as inhibitors of tissue proliferation in the developing ducts,
and as drivers of apoptosis and cell death in later involution stages (Moses and Barcellos-Hoff,
2011; Parvani et al., 2011). TGF- β activation has also been shown to decrease the number of basal
cells in the mammary gland through ROBO1/SLIT signaling (Macias et al., 2011). SLITS are a
conserved class of ligands that signal through ROBO receptors and guide axon formation and
branching. In the mammary gland they have been shown to act as tumor suppressors by inhibiting
canonical Wnt signaling (Marlow et al., 2008; Prasad et al., 2008). Furthermore, loss of SLIT/ROBO
signaling leads to premature mammary branching (Macias et al., 2011). This inhibitory capacity of
TGF- β is relevant to the developing mammary gland because it’s a primary regulator of lateral
branching in the developing duct through its ability to block local proliferation. Therefore, any
changes to TGF- β or its downstream targets could change the degree and extent of lateral
branching in mammary development.
The Wnt gene family play an important role in lateral side branching. Specifically, Wnt5A and
Wnt5B signal non-canonically and inhibit branching morphogenesis and stem cell activation in the
developing gland mammary gland (Roarty and Serra, 2007; Yu et al., 2016). Wnt5a is one of the
downstream targets of TGF-β-1 activation (Wakefield et al., 2001) . Wnt5 activation is mediated
through Ror2 receptor activation and sh-RNA deletion of Ror2 receptor leads to increased lateral
side branching (Roarty et al., 2015). While non-canonical Wnt signaling has an inhibitory effect in
the mammary gland, canonical Wnt signaling through Wnt4 is needed for mammary regeneration
in the luminal cell line (Yu et al., 2016). Indeed, Cai et al found that knockout of Wnt4 and Rspo1,
a Wnt family agonist, ablated the regenerative capacity of mammary cells when transplanted (Cai
et al., 2014). The Wnt family plays important roles in all stages of mammary development from
embryogenesis to ductal outgrowth is fundamentally required in lateral side branching (Brennan
and Brown, 2004; Rajaram et al., 2015; Yu et al., 2016).
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Figure 2. Schematic of branching models: a) lateral branching b) planar bifurcation c) orthogonal
bifurcation d) trilobed/trifurcation (modified from (Iber and Menshykau, 2013) (Blue boxes
represent 3-dimensional perspective of the growing buds with planar bifurcation growing in a flat
plane and orthogonal bifurcation alternating between flat horizontal plane and vertical plane. Red
tips represent the extending terminal end buds)
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Molecular Signaling in Mammary Proliferation
One of the primary pathways used for growth in the mammary ductal tree is the estrogendependent amphiregulin (AREG) pathway (Sternlicht and Sunnarborg, 2008). This pathway is
initiated by activation of estrogen receptor by ovarian estrogens; this leads to a cascading event
that increases the production of membrane bound amphiregulin. Amphiregulin is then cleaved by
the G-coupled protein ADAM-17 whereupon a released domain then moves to bind to Epidermal
Growth Factor Receptor (EGFR) on the surface of a nearby stromal fibroblast. AREG may also bind
to EGFR in a paracrine fashion on another epithelial cell (Aupperlee et al., 2013; Sternlicht and
Sunnarborg, 2008). EGFR then dimerizes and induces the release of FGFs from the stromal cell
into the stromal-epithelial cleft where they can then bind to the epithelial cells’ FGFR. This
paracrine process leads to local proliferation within the mammary gland (Aupperlee et al., 2013;
Vonderhaar and Greco, 1979). EGFR ligand-activated proliferation is primarily relevant in puberty
and early pregnancy because it aids in elongation of side branching and formation of budding
(Aupperlee et al., 2013). This paracrine pathway is necessary in puberty due to the increase in
lateral side branching and need to maintain the mammary architecture in the event of damage or
change (Aupperlee et al., 2013; Vonderhaar and Greco, 1979).

Pregnancy and Lactation

The onset of pregnancy stimulates a change in the hormonal profile with increases in levels of
estrogen and progesterone (Brisken and O’Malley, 2010; Richert et al., 2000). Once this switch is
achieved, a sizeable increase in proliferation occurs in the mammary gland. This proliferation
leads to increased side branching until the fat-pad is almost entirely filled with the ductal network
(Richert et al., 2000). Following this, differentiation occurs wherein the ends of new and old ductal
structures begin forming functional alveoli which will be the site of milk production (Oakes et al.,
2006). Alveoli are bulbous structures composed of an inner luminal epithelial cell layer that
becomes distended in late pregnancy, and an outer myoepithelial layer which is connected to the
basement membrane. The inner epithelial cell layer produces milk when stimulated and secretes
it into the lumen of the alveolus (Anderson et al., 2007; Oakes et al., 2006; Richert et al., 2000),
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while the myoepithelial cells contract and push the milk into the duct. Another feature of the
inner luminal layer is that it is interconnected by tight junctions while the cells are highly polarized.
The cytoplasm of the inner epithelial cells mostly consists of endoplasmic reticula which aids in
production and secretion of milk (Anderson et al., 2007). Milk production continues until weaning
occurs and the pups no longer require milk. Restructuring of the mammary gland during
pregnancy involves a decrease in the adipocyte ratio of the fat-pad. The adipocyte ratio is the
percentage of adipocytes in the mammary gland as compared to the epithelium. Furthermore,
this drop in the ratio is followed by expansion of the epithelial cell population. This decrease in
the total number of adipocytes creates the room needed for alveolar development. While puberty
is driven mainly by estrogen, pregnancy and lactation are under control of progesterone and
prolactin respectively (Richert et al., 2000; Vonderhaar and Greco, 1979). Progesterone drives the
increase in lateral branching that leads to filling of the fat pad as well as the differentiation and
restructuring required to form alveoli. (Anderson et al., 2007; Hens and Wysolmerski, 2005). In
Progesterone Isoform B negative mice lobuloalveolar development of the mammary gland is
reduced, with lateral branching and alveolar development being significantly reduced through
decreased proliferation and loss of epithelial content (Mulac-Jericevic et al., 2003). Prolactin is
the primary driver of differentiation in the mammary gland and works through the Jak-Stat
pathway (Hughes and Watson, 2012; Watson and Burdon, 1996). Pregnancy and lactation are
stages of significant gland remodeling and differentiation which are needed for efficient milk
production. The production of milk and state of lactation will continue until the suckling stimulus
is removed, at which point the gland will be remodeled back to its pubertal state.

Involution
Involution is a stage of mammary development characterized by apoptosis and structural
remodeling to revert the gland back to its pre-pregnant stage. Involution is triggered by removal
of the suckling stimulus and accumulation of milk (Marti et al., 1997; Watson, 2006a). As
involution begins, the secretory epithelial cells start to gain large vacuoles that contain fat
droplets and casein protein. The presence of milk in the alveolar lumen triggers the expression of
TGF-β-3 and leukemia death factor which activate Stat3 (Chapman et al., 2000; Hughes and
Watson, 2012). Flanders et al has shown that TGF-β-3 is an initiator of apoptosis necessary for
10

triggering involution in the mouse mammary gland (Flanders and Wakefield, 2009). Enzymatic
destruction of accumulated vacuoles and activation of Stat3 both lead to cell apoptosis in the
luminal epithelium, debris and secretions are then subsequently shed into the alveolar lumen (Li
et al., 1997; Watson, 2006a). The cells shed into the alveolar lumen are cleared by macrophages,
that then begin aggregating towards the alveoli (O’Brien et al., 2012). The process is reversible up
to 48 hours, at which point, restructuring of the gland occurs and the second irreversible stage of
involution begins (Lund et al., 1996). The second stage of involution is marked by collapse of the
alveoli and migration of adipocytes back into the fat-pad to differentiate into mature adipose
tissue. MMPs play a significant role in the second irreversible stage of involution by breaking down
the extra-cellular matrix around alveoli and activating Plasmin which allows for differentiation of
adipocytes (C.H.Streuli, 1996; Green and Lund, 2005). MMPs are under tight regulatory control by
Tissue Inhibitors of Metallo-Proteases (TIMPS) due to their importance in involution. In TIMP
deficient mice, involution is accelerated and no longer reversible in the first stage due to faster
activation of MMPs. As remodeling continues and epithelial cells are replaced by differentiating
adipocytes, macrophages remove accumulated cell debris through phagocytosis (Green and Lund,
2005; Lund et al., 1996). The basement membrane and myoepithelial cells attached to it are
preserved through survival signals activated by several hormonal cues (Li et al., 1997; Watson,
2006b). By day 21 of involution the gland has been remodeled back to its pre-pregnant stage, but
it maintains a level of differentiation higher than that of virgin mice at similar ages. This process
and the ability of mice to undergo continuous and cyclic development hints at the likelihood of
stem cell progenitors within the mammary architecture (Richert et al., 2000).

Mammary Stem Cells in the Adult Gland
The adult mouse mammary gland is a heterogenous structure that contains several different cell
types with different proliferative and differential capacities (Richert et al., 2000). All mammary
cells are derived from the differentiation of totipotent fetal stem cells which then become
common short term and long-term repopulating progenitor cells. These cells are characterized by
their Estrogen- (ER-) and Progesterone Receptor (PR-) negative-status and are known to be
multipotent (Visvader and Stingl, 2014). Serial dilution experiments have shown that one
mammary stem cell can recapitulate the entire mammary gland in a cleared fat-pad (Visvader and
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Stingl, 2014). This mammary stem cell population is characterized by staining for CD49fhi CD29hi
CD24+/modSca1low (Visvader and Lindeman, 2006; Visvader and Stingl, 2014) Characterization of
cell populations by presence and absence of specific markers is valuable in determining cell types
and their derivatives (citation). CD24, for example is a signal transducer glycoprotein known to
modulate growth and its absence has been associated with aggressive mammary tumors ((Hilska
et al., 2005)) .Isolation of this population of cells is complicated by the fact that certain
differentiated cells also express a similar surface marker expression profile (Visvader and
Lindeman, 2006). Mammary stem cells (MaSCs) divide asymmetrically, one daughter cell
remaining a MaSC while the other becomes a more differentiated cell. This process allows MaSCs
to produce both types of progenitor lines, luminal and basal, while maintaining the original stem
cell population. Asymmetric division is therefore necessary for maintenance of mammary stem
cells and to preserve future capacity for a rapid expansion of progenitors, which can then quickly
recapitulate any lost mature cells through symmetric division (Ercan et al., 2011; Visvader and
Lindeman, 2006). It is proposed that long term- and short term-repopulating stem cells are able
to differentiate into luminal lineage stem cells and basal lineage stem cells, which are multipotent
and can give rise to their own progenitor populations. Quantifying and classifying different
progenitor cell types in the mammary gland is difficult due in part to the fact that receptor staining
is measured by relative abundance of certain markers rather than absolute presence or absence
(Visvader and Lindeman, 2006). Myoepithelial progenitor cells proliferate symmetrically to rapidly
produce differentiated and mature myoepithelial cells. Myoepithelial cells are basal cells that sit
on the outside of the duct and behind luminal cells; they are in direct contact with the basement
membrane resting closer to the fibroblast rich stroma and adipose rich fat pad exterior (Visvader
and Lindeman, 2006). Myoepithelial cells also play a functional role in lactation by contracting and
helping push the milk inside the lumen of the alveolus into the duct. These cells can be visualized
by staining for specific markers such as CD29hiCD49fhiCD24+EpCAMlo/med (Visvader and Lindeman,
2006; Visvader and Stingl, 2014). The luminal epithelial lineages have two known progenitors that
both rapidly divide to replenish their mature progeny. The luminal cell lineage has a proposed
common progenitor stem cell line that can asymmetrically produce a ductal progenitor and early
alveolar progenitor luminal cell which can be stained with CD49f*CD29loCD24+/hiepCAMhiCD61ckitSca1+CD49b+CD14+and

CD49f*CD29loCD24+/hiepCAMhiCD61c-kitSca1-CD49b+CD14+ALDH+

respectively (Visvader and Lindeman, 2006; Visvader and Stingl, 2014). Ductal progenitor cells
divide and differentiate directly into mature ductal luminal cells which lines the inside of the
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mature mammary ducts and secretes extra cellular matrix necessary for the integrity of the ductal
structure.

(Shehata
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Visvader and Stingl, 2014). The plasticity and heterogenous nature of the mouse mammary gland
is largely responsible for why this organ is capable of continuous development throughout the
lifecycle of the animal.

Table 1 Mammary Cell Types. Cell types present in the mammary gland and their respective
staining markers.

13

Tumor Susceptibility and Abnormal Mammary Development
Due to the nature of mammary development and the complexity inherent in all its stages, there
are many time points where mammary gland development can be mis-regulated. In general,
abnormal organ development leads to susceptibility to illness, both cancer and otherwise; the
mammary gland is no exception to this rule (Ercan et al., 2011; Veltmaat et al., 2013).
Epidemiological studies in adolescent girls have found that pubertal development is a significant
time point for increased susceptibility to breast cancer and tumorigenesis (Biro and Deardorff,
2013; Bodicoat et al., 2014; Johnson et al., 2013). The reason for this is that pubertal development
activates a series of hormonal and adrenal pathways that lead to proliferation and changes in
structure and morphology of the gland (Brisken and O’Malley, 2010; Richert et al., 2000; Saji et
al., 2000). Dysregulation in the balance of proliferation and expansion of the known stem cell
populations in puberty can be one transition to tumorigenesis due simply to hyperplasia and
eventual neoplasia (Bodicoat et al., 2014; Ercan et al., 2011). Increased proliferation requires DNA
synthesis and subsequent cell division which are under the control of cell cycle regulators and
tumor suppressors such as BRCA1 and BRCA2 or PTEN (Narod and Salmena, 2011; Shore et al.,
2016). When tumor suppressors that limit DNA damage by arresting the cell cycle are mutated or
mis-regulated any increase in proliferation can increase the potential for mutations and initiation
of breast cancer. Once an initiating event has occurred most cancers will often have a latency
period. A latency period is the time that the tumor is establishing itself in the tissue and has no
physiological effects. During latency period the tumor may vascularize and transition through its
multiple stages of aggressiveness. The latency period ends when a diagnosis is made, which can
be multiple years after the initiating event and at multiple stages. Therefore, modelling latency
periods can give insight into appropriate screening times as susceptibility to cancer increases with
age (Olsson et al., 2003). While rarer, breast cancers among young women were found to be more
aggressive with poorer prognosis than those found among women over 40 (Johnson et al., 2013).
In mice, as in humans, a susceptibility window for tumorigenesis and breast cancer exists during
puberty. Gang Li et al 2002 found that when PTEN, a known tumor suppressor, is knocked out in
the mammary gland, the gland fails to differentiate properly and begins to hyper-proliferate (Li et
al., 2002). This increase in proliferation and poor differentiation are accompanied by increased
side branching and ductal elongation and finally tumor formation. This study perfectly
demonstrates the transition from hyperplasia to neoplasia. Shore et al shows that when PTEN is
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knocked out of only luminal epithelial cells the gland has transient developmental effects (Shore
et al., 2016). A loss of polarity and a failure in proper distribution of luminal cells accompanied by
disrupted mammary architecture in the mature gland are two of the primary effects seen (Shore
et al., 2016). Proper mammary development is therefore an essential process in maintaining a
functional adult mammary gland and avoiding cancer (Moser et al.; Russo et al., 1979).

The Cell Cycle
The cell cycle is complex system of phases, checkpoints and proteins that allow a cell to divide. It
serves a fundamental role as the primary and interconnected system needed for any cellular
reproduction (Schafer, 1998; Teyssier et al., 1999). The cell cycle consists of four primary stages:
G1, S, G2 and M. G1 stands for the Gap1 stage during which growth and total cell content
increases (Cowin and Wysolmerski, 2010; Schafer, 1998). If there are any cellular imperfections
or damage the cell is arrested in G1 by specific checkpoint proteins known as cell cycle inhibitors
or CKIs (Schafer, 1998). Nakayama et al. found that when certain checkpoint proteins, such as a
Kip1 family member, are knocked out, the cell cycle progresses haphazardly leading to organ
hyperplasia and pituitary tumors (Nakayama et al., 1996). After G1 cells enter the synthesis or S
phase, DNA replicates rapidly in anticipation for cell division. Cells then enter the final gap phase
of G2; cells undergo more growth and protein synthesis until the appropriate size is reached for
them to divide. As cells wait in G2 there is an increase in phosphorylated checkpoint kinases .This
accumulation of phosphorylated checkpoint kinase complexes is the key determining factor in G2
that will lead the phase transition to M (Porter and Donoghue, 2003). The final phase is mitosis or
M phase which culminates in the separation of two identical daughter cells, each with their own
copy of the parent DNA. Finally G0 is a unique stage of the cell cycle that effectively removes the
cell from continuous replication (Barnum and O’Connell, 2014). This process was originally
thought to occur in cells that were nutrient deprived or otherwise under stress and was therefore
coined as a resting phase. G0 is now better understood as its own specific stage outside the classic
cell cycle that has important functions in many organ systems. The G0 stage can be either
reversible or irreversible depending on the cell type and reason for entering (Rodgers et al., 2014).
Reversible G0 is known as quiescence, a state that stem cells will often sit in until cues from local
cell types drive them to re-enter the cell cycle and proliferate. Irreversible G0 states include both
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senescence and differentiation where cells such as mature neurons or terminally differentiated
mammary fibroblasts can no longer divide, but instead provide functional roles to local
architecture (Harashima et al., 2013).

CDKs, Cyclins and CKIs
The cell cycle and its drivers require complex and intricate checkpoints, otherwise cell division
could easily spiral into increased proliferation which can lead to genomic instability (Malumbres
and Barbacid, 2009). Cyclin dependent kinases (CDKs) are a class of serine-threonine kinases that
play vital roles in the cell cycle (Schafer, 1998). CDKs are vital due to their ability to phosphorylate
and activate a large array of proteins involved in the intricate steps and decisions of cell division
(Malumbres and Barbacid, 2009). Subsequently, these cascading signaling events activate DNA
which then encode protein products that allow for progress past cell cycle checkpoints. There are
8 total CDKs that have been characterized with 4 of them being the most well characterized. These
are CDK1, CDK2, CDK4 and CDK6 (Schafer, 1998). Cyclins are a class of proteins that act as coactivators of CDKs (Harashima et al., 2013; Noble and Endicott, 2001). Cyclins were discovered
after CDKs (Jackson, 2008). There are a variety of known cyclins, each with their own semi-specific
CDK binding partner and time point of high abundance in the cell cycle (Harashima et al., 2013;
Noble and Endicott, 2001). CDK expression remains constant during the progression of the cell
cycle, while cyclins shift in their production and degradation depending on the stage of the cell
cycle (Harashima et al., 2013). For example, the transition between G1 to S is under the regulatory
control of the CDK2-CyclinE complex which phosphorylates target proteins specific for transition
to S phase. The transition from G2 to M is similarly under the control of the CDK1-CyclinB complex
which determines when the transition from G2 to M occurs. Similarly, CDK4 and 6 are responsible
for moving the cell cycle through the early stages of G1 to S while also having the ability to arrest
the cell cycle if the conditions for cell cycle progression are not ideal; these conditions being
nutrient availability, cell damage and environmental conditions (Borel et al., 2002).
The balance of CDK-cyclin complex activation is complex and highly regulated by a variety of genes
(Barnum and O’Connell, 2014; Harashima et al., 2013; Schafer, 1998). All CDKs are defined by
having a cyclin binding P-STAIRE domain in the C-terminus. This domain is an ATP-binding catalytic

16

cleft and a catalytic site obstructing T-loop motif (Lim and Kaldis, 2013). CDKs are activated by
cyclins through a two step process which first involves binding of the cyclin to the P-STAIRE
domain of the CDKs. This first step leads to a conformational change that exposes the T-loop by
pulling it off the active site and flattening it towards the cyclin, which allows the CDK to be
phosphorylated and activated. During step two, phosphorylation of the CDK by CDK activating
kinases (CAKs) occurs on a threonine residue of the T-loop close to the catalytic site, which now
fully activates the CDK and allows it to phosphorylate its own targets. In the specific case of CDK2,
activation occurs when threonine 160 of the T-loop is phosphorylated which flattens the T-loop
and brings it close sterically to the cyclin (Malumbres, 2014). This post-translation change opens
the catalytic site of CDK2 which maintains a binding preference for S/T-P-X-K/R consensus
sequences (Malumbres, 2014; Martinez et al., 1997). Furthermore, while this preference
accommodates prolines in position 1 but it is far less stringent in position 3. (Noble and Endicott,
2001) . CDK inhibitors (CKIs) are a family of proteins that can inhibit either the CDKs directly or
CDK-Cyclin complexes to arrest the cell cycle during its respective phase. The INK4 family of
proteins, which includes: p15, p16, p18, p19, are all capable of targeting CDK4/6 and arresting the
cell cycle in G1 (Cánepa et al., 2007). The second family of CDK inhibitors is the Cip/Kip family
consisting of: p27, p21 and p57 (Nakayama and Nakayama, 1998; Quereda et al., 2016). The
Cip/Kip family can inhibit Cyclin-CDK complexes by obstructing a substrate binding domain on the
cyclin subunit called the MRAIL motif and subsequently binding to the catalytic cleft of the CDK
thereby inhibiting ATP binding (Besson et al., 2008). In mammals the Cip/Kip family primarily
targets CDK2 and its binding partners cyclin A and E (Denicourt and Dowdy, 2004). While arresting
the cell cycle is the primary role of CKIs, they can also stabilize and aid in the binding of some 11
CDKs to their cyclins, such as the stabilizing effect p27 has on CDK4/6 binding to Cyclin D
(Denicourt and Dowdy, 2004). Therefore, CKIs play a very vital role in the regulation of the cell
cycle. p27 specifically, is involved in arresting the cell cycle indefinitely in circumstances of cell
aging, (Barnum and O’Connell, 2014; Flores et al., 2014; Malumbres and Barbacid, 2009).

SPDYA/Spy1
Spy1 is a cyclin-like protein that drives the cell cycle and overrides specific cell cycle checkpoints,
such as the Cip/Kip family. Also known as X-Spy1 or Ringo, the Spy1 protein was originally
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discovered in a screen of a Xenopus laevis cDNA library in a rad1 deficient strain of S.Pombe. The
objective was to find cDNAs that encoded factors that would help this genetically deficient yeast
line to recover from UV radiation damage (Lenormand et al., 1999). Rad1 is a checkpoint DNA
repair protein that combined with Rad10 can form an endonuclease capable of degrading single
stranded DNA. Furthermore, in the event of DNA damage Rad1 is needed for the yeast to
transition past the G2/M checkpoint as it functions to repair DNA. (Schiestl and Prakash, 1988;
Tomkinson et al., 1993). With a deficiency in rad1 damaged arrest at the G2/M checkpoint, an
effect that will be lethal if the DNA is not repaired. A Xenopus laevis cDNA library was used to
identify genes that were able to push past the checkpoint and confer resistance to DNA damage.
Xenopus-Spy1 (X-Spy1) was isolated due to its ability to drive the cell cycle past the G2/M
checkpoint even in the event of DNA damage. (Lenormand et al., 1999; Nebreda and Hunt, 1993).
In Xenopus, oocyte maturation is a two-step process with the first step arresting oocytes in G2/M
at the first meiotic division. In the presence of progesterone, the cell cycle continues, and oocytes
enter meiosis I and are arrested again at M stage of meiosis II until fertilization (Lenormand et al.,
1999) The labs of Dr. Angel Nebreda and Dr. Donoghue also found that X-Spy1 could activate
CDK1 to drive the cell cycle forward in G2 arrested Xenopus oocytes when its primary driving
hormone progesterone was absent (Ferby et al., 1999; Lenormand et al., 1999). Interestingly, it
was also found that when X-Spy1, known also as p33RINGO, was silenced using antisense
oligonucleotides the oocytes were delayed in their maturation, even after induction with
progesterone (Ferby et al., 1999). This data led researchers to conclude that X-Spy1 played a role
in Xenopus oocyte maturation and subsequent release from G2 block. It was also found that XSpy1 had no sequence homology with known cyclins and CDK activators but can activate CDK2 in
the process of oocyte maturation. (Karaiskou et al., 2001; Lenormand et al., 1999). Through
studies focusing on deletion mutants of X-Spy1 it was found that amino acids 54-218 constitute a
functional “Speedy/Ringo box (S/R box)” which is necessary for its binding to CDKs. The human
clone of SPY1 was isolated using testis cDNA library focused on identifying genes with high
homology to X-Spy1 (McGrath et al., 2017). The human homologue of X-Spy1, SPDYA had 40%
homology to X-Spy1 and over 60% homology for its functional central region. To test if the human
homologue of X-Spy1 has the same functional properties, mRNA of human Spy1(SPY1) was
injected into Xenopus oocytes and found to induce G2/M transition therefore confirming that the
homology is functional (Barnes et al., 2003; Porter et al., 2002). There are at least six known
mammalian Spy1/Ringo homologues all sharing around 50% homology within the S/R box (Cheng
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et al., 2005a; Dinarina et al., 2005). There have been no homologues of Spy1 identified in yeast,
worms, flies or plants. In humans, Spy1 is expressed in a variety of tissues. (Barnes et al., 2003;
Cheng et al., 2005a). Further investigation into human Spy1 revealed 5 family members of the
Spy1/Ringo family, with the original characterized Spy1 being Speedy/Ringo A. Spy1/Ringo A was
shown to have two isoforms, Speedy/Ringo A1 and A2. Spy1A1 was found to be identical to the
originally identified human SPY1 and will be referred simply as Spy1 from here on (Cheng et al.,
2005b; Porter et al., 2002). Upregulation of Spy1 in cell lines leads to increased proliferation and
activation of CDK2 at the G1/S checkpoint (Porter et al., 2002). Furthermore, inhibition of CDK2
negated the effect of Spy1 upregulation thereby demonstrating its effect as a binding partner
(McAndrew et al., 2009). Unlike traditional cyclin binding mechanisms, Spy1 activation of CDKs is
functionally unique. Traditional CDK activation begins with cyclins binding to the CDK and inducing
a conformational change by exposing the T-loop and pulling it off the catalytic cleft. The T-loop is
then typically phosphorylated on a threonine residue near the CDK active site and the flattened
conformational change away from the catalytic site is maintained which fully activates the CDK
(Barnum and O’Connell, 2014). Spy1 can activate CDKs by binding and changing the conformation
so that T-loop phosphorylation is unnecessary for full activation and localization of the CDK (Cheng
et al., 2005b; McGrath et al., 2017; Porter et al., 2002). In characterizing the 3D structure of Spy1
McGrath et al showed that the CDK2 T-loop was moved 5-6 Angstroms (Å) off the catalytic cleft
when bound to Spy1 (McGrath et al., 2017). Furthermore, Spy1 subunit T136 was found to be
bound to CDK2 T-loop Threonine 160 and subunits D97 and T134 were bound to CDK2’s T158 and
D159 which are typically sterically inaccessible in an inactive CDK. In comparison to cyclin A, Spy1
formed several unique binding interactions with CDK2 which likely facilitate its ability to expose
the catalytic site and coordinate the CDK (McGrath et al., 2017). This effect of Spy1 was also
demonstrated when Cheng et al. showed CDKs with mutated Thr160 and Thr161 residues were
activated in the presence of Spy1 (Cheng et al., 2005b). The reason for Spy1’s ability to activate
CDKs in a non-traditional manner, even though its binding patterns are not unique, is due to the
conformation change it induces in the target CDKs bound (Cheng et al., 2005b; Karaiskou et al.,
2001; McGrath et al., 2017).
Spy1 is also unique to other cyclins through its interaction with CKIs. CKIs play important roles in
regulating the cell cycle and arresting it at specific checkpoints. Spy1 activation of CDK2 has been
shown to be less susceptible to inhibition by p21, a member of the G1 arresting Cip/Kip family
(McAndrew et al., 2009). Furthermore, Spy1 has been shown to interact with p27, another
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member of the Cip/Kip family, and to increase its turnover rate in the G1/S phase. Spy1 increases
the turnover of p27 through phosphorylation on its Th187 residue, consequently targeting it for
degradation (Al Sorkhy et al., 2016; McGrath et al., 2017). Sorkhy et al also demonstrated that a
p27 inhibitory interaction with CDK2-Cyclin complex was weaker when bound to Spy1. This could
be due to Spy1 lacking a hydrophobic binding motif found on many cyclins called the MRAIL site
(McGrath et al., 2017). Collectively, Spy1 is a versatile driver of the cell cycle due to its ability to
activate CDKs independent of phosphorylation and degrade and negate the effects of CKIs.
The expression of Spy1 is under tight regulatory control by a class of proteins known as ubiquitin
ligases. E3 Ubiquitin ligases are proteins that can attach multiple small regulatory ubiquitin
proteins to their targets and mark them for degradation by the proteasome. Furthermore, the
proteins known as “ubiquitin ligase neural precursor cell expressed developmentally downregulated protein 4” and the “Skp, Cullin F-box containing complex” (Nedd4 and SCF) are two
proteins which control the levels of Spy1 through degradation (Sorkhy et al., 2009).The SCF
complex is a E3 ubiquitin ligase that drives the cell cycle by poly-ubiquitinating CKIs and marking
them for proteasomal degradation. It targets Cip/Kip family members p27 and p21 specifically as
well as Cyclin E. Dinarina et al. showed that in non-synchronous cells, SCF inhibition, but not the
anaphase promoting complex (APC/C), will lead to accumulation of Spy1 (Dinarina et al., 2009).
The other known Spy1 inhibiting ubiquitin ligase NEDD4 is a widely expressed regulator shown to
be vital in neural morphology and organ development (Cao et al., 2008). Through co-immuno
precipitation NEDD4 was shown to interact with Spy1 in-vivo. Furthermore, Spy1 ubiquitination
was significantly decreased in the presence of ubiquitin non-binding dominant negative mutant
of NEDD4 (Sorkhy et al., 2009). In contrast to X-Spy1 human Spy1 degradation requires
phosphorylation on its N-terminal domain with the C-terminus being dispensable (Sorkhy et al.,
2009). Spy1 abundance was shown to be proteasome-dependent with lack of N-terminal
ubiquitination leading to higher protein stability (Sorkhy et al., 2009). Due to Spy1’s myriad of
effects, its expression in the developing mammary gland is therefore likely very important as misregulation could have a variety of consequences on the morphology of the gland.
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Spy1 and Mammary Development
Endogenous expression of Spy1 in the developing mammary gland follows a cyclic trend and
correlates with periods of development characterized by increased proliferation and apoptosis
(Golipour et al., 2008). Spy1 is highly expressed during early stages of development such as prepubescent growth all the way into early pregnancy. The levels of Spy1 start to decrease during
late pregnancy and into lactation as the gland differentiates and develops functional alveoli (Al
Sorkhy et al., 2012; Golipour et al., 2008). Decrease in Spy1 abundance during differentiation was
confirmed both with a time-course study and by using HC11 cells as a model system. HC11 cells
are an immortalized mammary epithelial cell line that responds to similar cues in-vitro as would
lead to differentiation or proliferation in-vivo (Ball et al., 1988). Golipour et al found that when
Spy1 is overexpressed during differentiation in HC11 cells there is earlier expression of β-casein,
a milk protein known to delineate differentiation in mammary development (Golipour et al.,
2008). During involution Spy1 levels begin to rise again until reaching levels in the adult gland
(Golipour et al., 2008). It was also found that when fat-pad transplants are done with Spy1
overexpression in HC11 cells into the cleared glands of 3-week-old mice, the glands show
increased staining with markers such as PCNA as well as hyperplasia and disruption of mammary
architecture (Golipour et al., 2008). Spy1 up-regulated cells grow in a disorganized fashion with
loss of polarity and apical linearity (Golipour et al., 2008). Spy1 regulates the ER-α and ERK1/2
pathways to promote resistance to anti-estrogen chemotherapeutic tamoxifen (Ferraiuolo et al.,
2017). Elevated Spy1 levels were found in many types of aggressive human breast cancers,
specifically triple-negative and Her2 negative breast cancers (Al Sorkhy et al., 2012). When using
a non-degradable Spy1-TST mutant (developed with alanine mutations at Tyrosine 15 Serine 22
and Tyrosine 33), Al Sorkhy et al. found increased likelihood of tumorigenesis demonstrating the
importance of Spy1 in possible breast cancer initiation (Al Sorkhy et al., 2012). With all the
evidence showing the effects of Spy1 expression in the mammary gland and its potential initiating
capacity in tumorigenesis it’s likely that Spy1 serves important functional roles both in mammary
development and maintenance. Therefore, further elucidation of its roles and the pathways it
affects is required.
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Transgenic Mouse Models
Transgenic animal models are a cornerstone development of modern molecular biology
(Haruyama et al., 2009). There is no shortage of pathways, phenotypes or conditions that can be
investigated using transgenic mouse models. The development of transgenic models in the early
1970s ushered in the modern application seen today in genetics, cancer and developmental
studies (Doyle et al., 2012). The first transgenic mouse was developed using pro-nuclear
injections. Pronuclear injections insert a DNA construct directly into the recently fertilized mouse
egg, while the maternal and paternal DNA are still separate. Pronuclear injections cannot
guarantee the location of gene insertion or the number of gene inserts. Using this technique, the
first transgenic mouse was developed in the 1980s by Dr. Jon W Gordon (Gordon et al., 1980).
While unsuccessful in expressing the gene in question, the breakthrough did lead to the first
mouse with a visible phenotype from pronuclear injection (Doyle et al., 2012; Hanahan et al.,
2007; Haruyama et al., 2009; Jones, 2011). The technique was then refined over time and injection
of double stranded DNA encoding the gene in question within a vector to drive its expression
using endogenous housekeeping genes was developed. An example of this would be a transgenic
mouse with the aim of expressing its transgene constitutively in alveolar type 2 cells would utilize
a surfactant protein C promoter. (Doyle et al., 2012; Haruyama et al., 2009). Eventually the
development of inducible gene expression was developed wherein a gene in question is under
the control of an activated promoter, such as human Cytomegalovirus promoter (Schottstedt et
al., 2010); this system allows for the gene to be expressed transiently or at specific time-points in
the lifecycle of the organism (Doyle et al., 2012; Sun et al., 2007).
While transgenic animal models are useful in the field of molecular biology they do come
with certain drawbacks. Firstly, the inserted DNA must be injected into the pronucleus before the
first cleavage of the zygote (Doyle et al., 2012). If the first cleavage occurs and DNA begins to
double in the organism before the DNA of interest can be inserted, the animal will be a genetic
(and presumably phenotypic) mosaic. Furthermore, the gene in question inserts randomly into
the host DNA with a variable copy number which could lead to phenotypic effects arising from
disruption of local context at the insertion site. Moreover, the copy number of inserted genes
could lead to non-specific or unintended gene dosage effects. DNA insertion into a protooncogenes or other vital regulatory gene families disrupting their function can result in cancer
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and morphological defects (Ikink et al., 2018). Multiple insertions do not necessarily mean
significant increase in the transcription of the gene so analysis of gene transcription as a
confirmation is always necessary (Gordon et al., 1980; Liu, 2013). Finally, if the gene is inserted
into a heterochromatic region of the chromosome then its effects will be negated by the inhibitory
effect of the heterochromatin (Haruyama et al., 2009; Jones). Using multiple founder lines and
screening can help to circumvent and control for these effects, but they require the use of more
mice and resources. The transgenic mouse model remains a staple and indispensable research
tool for developmental and cancer studies.

Mouse Mammary Tumor Virus and Organ Specific Mouse Models
The mouse mammary tumor virus, MMTV, also known as the Bittner virus, is an oncogenic RNA
virus of the retroviridiae family (Matsuzawa et al., 1995). The virus primarily targets and functions
within the luminal alveolar cells and is transferred primarily from the milk of a mouse to another
mouse. It initially infects the spleen before transitioning to the mammary gland (Matsuzawa et
al., 1995). Within the mammary gland the virus causes tumorigenesis through insertional
mutagenesis, a process by which it disrupts an already established genome, and induces
subsequent activation of local oncogenes (JS et al., 2017; Taneja et al., 2009). One of the first
genes identified to be activated by the MMTV was Wnt1; since this initial discovery up to 6 other
oncogenes have also been identified (Cardiff and Kenney, 2011). The value in the discovery of the
mouse mammary tumor virus is the use of its driving ability as a promoter (Taneja et al., 2009).
Furthermore, MMTV is a mammary specific virus and therefore any gene constructs made using
the MMTV promoter to drive up-regulation are most likely to be limited to the mammary, as well
as other secretory organs such as kidneys, salivary glands, lungs and seminal vesicles (Muñoz and
Bolander, 1989; Ross et al., 1990). The long terminal repeat of the MMTV promoter contains a
hormone responsive element which is generally used in creating the myriad of provirus-integrated
MMTV driven transgenic models. One such model was created in 1984 and placed the protooncogene C-Myc under the control of the MMTV promoter leading to the MMTV-Myc mouse
(Stewart et al., 1984). This mouse developed mammary tumors after a year post-birth
demonstrating the effects of elevated Myc expression. The MMTV promoter is activated postbirth due to its hormone-responsive element and its activity increases in pregnancy due to the
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increase in systemic hormones such as prolactin, progesterone and other glucocorticoids (Ham et
al., 1988). The MMTV promoter is an incredibly useful tool for manipulating genes within mouse
models due to its specificity, constitutive activation and time-point activation.

Mammary Organoids, 3D culture and In-vitro models
Organoids are a relatively new and emerging technique. The idea of developing organoids began
in the 1980s when culturing protocols began using 3D versus 2D culture and allowing cells to grow
within various mediums (Ravi et al., 2015). Within the focus of mammary groups like Li et al. It
was found that when culturing mouse primary cells on 2D culture they lost their ability to produce
milk proteins even in the presence of lactogenic factors (Li et al., 1987). Subsequent studies
determined that when culturing cells in a gel formed of Collagen I, the mRNA for milk proteins like
β-casein increased (Li et al., 1987). With time, more complex organoid media containing Collagen
I/IV, Fibronectin and other factors were generated that better mimicked the microenvironments
of the modeled organs (Benton et al., 2009; Hughes et al., 2010). Gut organoids were some of the
first to be established and gave a great deal of insight into the nature of the cell-cell adhesions
and intricate signaling pathways necessary to differentiation (Date and Sato, 2015; Dutta et al.,
2017). The ability of organoids to approximate the in-vivo environment of an organ system allows
for the study of developmental mechanisms, differentiation states, and dynamics. This capacity
of organoids also gives insight into cancer progression. Mammary organoids from both primary
cells and cell lines are a useful model with several groups establishing their own (Jamieson et al.,
2017; Zhang et al., 2017). This mammary organoid system and its establishment could be used as
a high-throughput developmental system that could be easily manipulated with the factors added
in media.
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Hypothesis & Objectives
A known susceptibility window for cancer development and tumorigenesis during mammary
development is puberty. Spy1 is a protein that has a variety of roles to play both in development
and directly in driving the cell cycle and regulating proliferation.
We hypothesize that proper regulation of Spy1 is necessary for typical mammary development
and elevated levels of Spy1 can lead to increased proliferation in ductal and lobualveolar
development culminating in precocious mammary development. We further hypothesize that
elevated Spy1 levels in a cell organoid system will increase proliferation and bud formation.
We aim to address this hypothesis through the following two objectives
-

Characterize the effects on pubertal mammary branching, proliferation and finally the
role of Spy1 in puberty using the MMTV-Spy1 mouse model.

-

Dissect Spy1 effect on budding and branching using the Hc11 3D cell culture system.

This work will give new insight into the developmental effects and mechanistic effects of Spy1
using two different model system. This insight could be used to determine early indicator system
of susceptibility using Spy1 levels and any morphological effects.
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Materials and Methods

Mouse Maintenance
Mice were maintained following the Canadian Council on Animal Care Guidelines under the
animal utilization protocol 17-17 approved by the University of Windsor. Mice (aged 10 and up)
were sacrificed using a CO2 gas chamber and tissues were then extracted following CCAC
guidelines (Canadian Council on Animal Care, 2010).

Immunohistochemistry
Mouse inguinal glands were extracted and fixed overnight in 10% formalin at 4°C. The following
day the tissues were dehydrated through a series of increasing ethanol washes (70%, 95%, 100%)
for 2 hours in 70% ethanol and for 1 hour twice in 95% and left in 100% ethanol overnight. Tissues
were then cleared in xylene for 1.5 hours and embedded in paraffin wax (Richard-Allan Scientifictm
Histoplast Paraffin). Immunohistochemistry was performed as described in (Shore AN et al 2016
Dev Biol.). 5 µm sectioned slides were prepared from paraffin embedded mouse mammary glands
using a microtome. Tissues were deparaffinized in xylene for 3 washes at 3 minutes each and
rehydrated using descending ethanol concentrations (100%, 95%, 80% and 70%). Antigen retrieval
was performed using 10mM sodium citrate buffer (pH=6) with 20-minute microwave heating.
Endogenous peroxidases were quenched with 10% hydrogen peroxide solution. Blocking was
done with Anti-rodent MOM blocker (Biocare Medical) or 2% Goat serum in 0.5% tween PBS
solution for mouse and rabbit secondary antibodies respectively. Sections were incubated in
primary antibodies, amphiregulin (Antibodies-Online No. ABIN704996) (1:600) and anti-BrdU (BD
Biosciences No. 550891) (1:200) for 1 hour at 37°C and overnight at 4°C respectively. Biotinylated
secondary antibodies were used at a concentration of 1:750 and were diluted in MOM blocker or
0.5% Tween in 1x PBS and applied for 45 minutes at room temperature. Slides were stained using
ABC reagent kit (Vectastain ABC) and peroxidase activated 3,3'-diaminobenzidine substrate kit
(Invitrogen) following manufacturer’s instruction and left to stain for 10 minutes. Following DAB
staining slides were left in water for 10 minutes. Hematoxylin was used as a nuclear counterstain
and tissues were then dehydrated with a series of ethanol immersions (70%, 95%, 100%) and
finally cleared in xylene overnight. The following day the tissues were mounted with permount
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solution (Fisher Scientific SP15-100), imaged with Leica DMI6000 inverted microscope and
analyzed with ImageJ colour deconvolution software.

Immunofluorescence
Inguinal glands were extracted and fixed as previously mentioned. 5 µm tissue sectioned slides
were deparaffinized by two 30-minute washes in xylene. Tissues were then rehydrated using a
descending series of ethanol washes (100%, 95%, 80%, 70%), all of which were performed for 15
minutes. Antigen retrieval was performed using a 10mM sodium citrate buffer solution (Ph=6)
and microwaved (100°C) for 20 minutes. Following this, tissues were kept in Coplin glassware
under running water for 15 minutes. Tissues were blocked with Anti-rodent MOM blocker
(Biocare Medical) for 10 minutes. Sections were incubated with primary antibodies, anti-Spy1
(Abcam ab153965) (1:200) and anti-BrdU (BD Biosciences No. 550891) (1:200) overnight at 4°C
and 1 hour at 37°C respectively. Sections were washed three times with 1x PBS for 5 minutes and
blocked again between each application of primary antibody. Fluorescent secondary antibodies
were used at concentrations of 1:250 (and were diluted in MOM blocker or 1% BSA with 1:250
DAPI (thermo) and applied for 15 minutes at room temperature. Slides were then washed 3 times
with 1x PBS and mounted with anti-bleaching mounting medium (Vectashield). The following day
tissues were imaged with Leica DMI6000 inverted microscope with Leica AF software.

Mammary Line Maintenance
Mouse mammary epithelial cells, HC11, (Provided by Dr. C Shemanko) were maintained in RPMI
media (Hyclone) containing 10% New Born Calf Serum (vol/vol) (C8056; Sigma Aldrich),
supplemented with 10ng/mL EGF (Life Technologies) ,5μg/mL bovine insulin (Sigma) and 0.5%
Puromycin/Streptomycin (vol/vol). Cells were maintained at 5% CO2 at 37°C.

Plasmids and Constructs
The pHIV Zsgreen vector or pEIZ (18121) was received as a gift from Bryan Welm & Zena Werb
(Welm et al., 2008) while the pEIZ-Spy1 vector was generated as previously described (Lubanska
et al., 2014)and was utilized in Spy1 overexpression experiments HC11 mammary cell lines.
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Transfection
Transfection of HC11 mammary cell lines were performed as follows. Four hours prior to
transfection and at 80% cell confluence, growth media was removed and replaced with serum
and antibiotic free media. Cells were transfected using 25µg of polyethylenimine (PEI) and 12 µg
of plasmid DNA. The DNA and PEI mix were incubated at room temp for 10 minutes before dropwise addition to plate. Cells were then incubated for 18-24 hours before transfection media was
removed.

Generating Mammary Organoids
Mammary organoids were generated using HC11 cells transfected with pEIZ and pEIZ-Spy1
vectors. Collagen gel was prepared using rat-tail collagen I (BD Bioscience #354326). We mixed
217uL of Collagen 1 with 25µl DMEMx10 and 8ul NaOH 1N and mixed lightly. Pre-assembled
collagen solution was mixed until a pink colour was achieved, representing pH 7-7.5; pH was
tested and adjusted accordingly otherwise. 25uL of the pre-assembled collagen solution was used
to form a thin underlay on a 24-well plate. The plate was then incubated at 37 degrees until ready.
The pre-assembled collagen solution was incubated in 4 degree for 2.5 hours. Collagen and
Matrigel (Fisher Scientific Corning™ C356237; C354236 respectively) were mixed at a
concentration of 7:3. 2000 cells were seeded in 50uL of collagen: Matrigel mix and plated onto
the collagen underlay and incubated for 1 hour at 37 degrees. Specific media was then added to
their respective wells (RPMI, RPMI+EGF, RPMI+FGF).

HC11 and Primary Cell Organoid Analysis
HC11 cell organoids were considered mature upon reaching a size of >30 μm in diameter due to
their clear visibility (Nguyen-Ngoc et al., 2015). Mature organoids were then sorted into either
budding/stratified or non-budding groups and counted separately. In each media condition
(RPMIS, RPMI +EGF, RPMI +FGF), the budding/stratified organoids were divided by total counted
per image with four images randomly taken per time-point. All counting was done in ImageJ with
images exported into the software and counted.
Primary cell organoids were allowed to grow for two weeks before imaging and subsequent
paraffin embedding. Size was measured in primary cell organoids using ImageJ by determining
the length and width of each organoids per image and calculating the area in µm2. The branches
were counted per primary organoid and averages reported over three measurements.
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Quantitative Real Time PCR Analysis
RNA was isolated using Qiagen RNAeasy extraction kit as per manufactures instructions (Qiagen,
Cat.74106). Quality and concentration of RNA was analyzed with Nanodrop lite
Spectrophotometer (Thermofisher). Subsequent cDNA was made using Quanta qScript (II) as per
manufacturer’s instructions. Real time PCR was optimized for use of SyberGreen (Applied
Biosystems) and analyzed using Viia7 Real Time PCR system (Life Technology) and associated
software. The primers used were as follows:
Flag-Tagged Spy1 Forward 5’ TGACAAGAGGCACAATCAGATGT 3’
Flag-Tagged Spy1 Reverse 5’ CAAATAGGACGCTTCAGAGTAATGG 3’
Mouse GAPDH Forward 5’ GATGCCCCCATGTTTGTGAT 3’
Mouse GAPDH Reverse 5’ GTGGTCATGAGCCCTTCCA 3’

Whole Mount Production and Analysis
Extracted inguinal glands were placed on a positively charged glass slide (Thomas Scientific) and
left in Clarke’s solution (75% ethanol 25% acetic acid) overnight. Following this, the tissues were
placed in 70% ethanol for 30 minutes and moved into carmine solution (0.2% carmine alum and
0.5% potassium sulphate) until red stain was visible throughout the gland. Glands were then destained in a 1% HCl 70% Ethanol solution for 6 hours and dehydrated in increasing ethanol
concentrations (70%,95%,100%) for 15 minutes respectively. Tissues were cleared in xylene
overnight and mounted with Permount solution (Fisher Scientific SP15-100). Slides were imaged
using Leica MZFLIII dissecting microscope (Leica Microsystems) and data was captured using Leica
LASv4.3 Software (Leica Application Suite).

Mammary Epithelial Content Analysis
Mammary epithelial content analysis was done by exporting whole mount images of all
timepoints into ImageJ and then setting the image to 8-bit and grayscale. An image containing a
line measuring 1mm is used to set the mm to pixel conversion rate under the analysis tabs so that
the final measurement in ImageJ is equivalent to millimeters. Following this, the image tab is
selected, and the threshold tab is brought up. The threshold value is increased until the black
image covers the developing glands and tissues but not the entire whole-mount. This value is
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measured as the area of epithelial tissue. The threshold is then selected again and increased until
the entire whole-mount is covered. This value is measured and represents the total whole-mount
size. The percentage of epithelial tissue per whole-mount is acquired by dividing the first value by
the second.

Mammary Lateral Branch Analysis
Mammary lateral branch analysis was done by exporting time-point specific whole mount images
into ImageJ and setting the pixel conversion scale to the equivalent distance of the 50 um scalebar
in the image. Any measurements taken of the length using ImageJ were then converted to
millimeters. Five ducts were selected per image with the length and number of branches
measured.

BrdU Incorporation Assay
The 8-week-old MMTV-Spy1 mouse and its control littermates received an intraperitoneal
injection of 50 mg/kg of Bromodeoxyuridine (BD Pharmingen). 2 hours post injection the mouse
was sacrificed, and tissue was collected for histology. Once stained positive cells which expressed
brown colour in the nucleus were counted as positive and divided by the total number of blue
hematoxylin stained cells per gland.

Image Analysis and Quantification
ImageJ was used to quantify differences in protein densitometry from tissues stained with
immunohistochemistry. Once images were opened in imageJ software colour deconvolution was
selected and applied to H-dab setting with integrated density selected as the output. Only the
brown (DAB) and blue (Hematoxylin) channels were used; once a channel was selected the image
was limited to the threshold. Each image was then automatically adjusted to its threshold and the
value recorded. The values of the brown channel were divided by the blue control hematoxylin
channel to normalize each measurement. The normalized values were averaged to determine the
densitometry.

Statistical Analysis
Graphpad Prism 5.0 software was utilized for statistical analysis. Data is presented as differences
between the means and standard error. Two-way ANOVA was used for analysis of lateral
branching and total epithelial content in MMTV-Spy1 mice and control with Bonferroni’s post-hoc
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test to further elucidate time-point specific differences. Uneven n-values were normalized
through weighted means detailed in LD Fisher and G vanBelle (Brunner, 1998). Two-way ANOVA
with repeated measures was used for analysis of differences between organoid media conditions
with repeated measures and Bonferroni’s post-hoc within media condition. Students T-test was
used where applicable, such as analysis of immunofluorescence imaging in BrdU injected mice
and analysis of primary cell organoids, (* p<0.05) was considered as significant in all cases.
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Results
Spy1 upregulation causes increased lateral side branching and mammary density
Puberty is a developmental timepoint during which there is a known associated risk of breast
cancer as compared to other early life events (Bodicoat et al., 2014). A key feature of development
during puberty is expansion of the ductal network. Previous work has shown that MMTV-Spy1
mice have significant increase in the total number of lateral branches at 6 weeks of age (Fifield,
2015). Therefore, to assess the extent of Spy1 effects on lateral branching, we extracted inguinal
glands from MMTV-Spy1 and control littermates at 6, 8 and 12 weeks of age and whole mount
analysis was performed. Lateral branching was analyzed by assessing the number of lateral
branching points along the primary ducts. There was an overall effect of Spy1 up-regulation seen
between MMTV-Spy1 mice and their littermate controls. Specifically, at 6 weeks we saw a
significant 52% (p<0.05) increase in the number of lateral branches per mm of the primary duct.
This same result was seen in both 8 and 12-week glands with a 55% and 38% (p<0.005) increase
respectively (Figure 3A, B). Since there was an increase in lateral branching, we then investigated
whether this lead to an increase in epithelial content within the fat pad, which is a known marker
for tumorigenesis along with increased mammary density (Huo et al., 2015). We evaluated the
total epithelial cell content and found an overall increase in epithelial content in the MMTV-Spy1
mice as compared to the littermate controls. However, we did not find a significant difference at
any one specific time-point (Figure 3C).
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Figure 3: Whole Mount analysis of Control versus MMTV-Spy1 glands during puberty. A)
Representative images of carmine stained whole mounts from, 8 weeks and 12-week FVB mice
(6-week n=4, 8-week n=4, 12-week n=3). B) Analysis of wholemount images from control and
MMTV-Spy1 inguinal glands. Number of branches off the primary duct were counted and then
divided by the length of each primary duct to determine the proportion of branches/mm for i) 6
week ii) 8 week and iii) 12-week glands. C) Analysis of total epithelial content in area of ducts
divided by total area of fat pad with Bonferroni post-hoc showing differences at individual timepoints i) 6 weeks ii) 8 weeks iii) 12 weeks. (* = p<0.05) Error bars represent standard error SEM.
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Spy1 increases mammary epithelial proliferation and secretion of AREG in the
pubertal and adult mammary gland
Since Spy1 is known to increase proliferation (Porter et al., 2002), the increase in side branching
may be due to enhanced proliferation. To investigate whether or not Spy1 is enhancing
proliferation we intraperitoneally injected 8-week MMTV-Spy1 mice and their control littermates
with BrdU. After tissue extraction and IHC for anti-BrdU we found that the MMTV-Spy1 mice had
a significant increase in BrdU positive cells (p<0.05) over their littermate controls (Figure 4A, B,
Supplementary Figure 1A, B). Immunofluorescence co-staining for BrdU and Spy1 in developing
8-week glands revealed a higher proportion of nuclei in MMTV-Spy1 glands co-staining for BrdU
and Spy1 than their control counterparts (Figure 4.C, D). This data demonstrates that MMTV-Spy1
mice have increased rates of proliferation, and Spy1 significantly correlates with BrdU expression
in these mice.
We previously described the EGFR pathway involving the AREG agonist that is actively used in
mammary development, specifically in lateral branching and growth involving the ductal epithelial
cells. Previous work has shown that Spy1 can activate the estrogen receptor without the need of
its hormone ligand, therefore we wanted to investigate the role of Spy1 on this pathway to
determine if this may be contributing to the significant increase in proliferation seen. The
developing ducts of 6-week, 8-week and 12-week mice were analyzed for AREG expression via
immunohistochemistry and we found a main effect of Spy1 up-regulation as an overall higher
level of AREG in the MMTV-Spy1 glands versus their littermate controls. Specifically, there was a
significantly higher level of AREG at 12 weeks and a non-significant difference at 6-week. We
observed no difference in AREG in 8-week MMTV-Spy1 glands (Figure 4B, C). This data
demonstrates that Spy1 enhances proliferation and this may be due in part to alterations in EGF
and AREG signaling.
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Figure 4 MMTV-Spy1 mammary glands have higher proliferation and AREG levels: A)
Representative images of BrdU IHC staining in 8-week control and MMTV-Spy1 glands (Black and
white arrows represent positive BrdU and Brdu/Spy1 stained cells respectively). Scale bars
represent 100 µm and 50 µm respectively. B) Graphical representations of percentage of stained
nuclei divided by total nuclei in gland of 8-week control and MMTV-Spy1(n=3). C) Representative
images of AREG IHC in control and MMTV-Spy1 glands at 6, 8 and 12 weeks respectively (6-week
n=4, 8-week n=3, 12-week n=3) Scale bars represent 100 µm. D) Graphical representations of total
AREG staining normalized to hematoxylin. Raw densitometry values integrated using ImageJ. (* =
p <0.05, ** = p<0.01). Error bars represent SEM.
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Spy1 increases budding capacity in mammary epithelial cells
3D culture is a useful technique due to its ability to better replicate in vivo environments but offer
the ability to focus on specific aspects of those environments. Therefore, we turned our attention
to in vitro 3D to determine the ability of Spy1 to initiate lateral branching and proliferation by
narrowing the focus to its mechanistic ability to affect budding and growth using the mammary
epithelial cell line, HC11 (Figure 5). We overexpressed Spy1 in HC11 cells using a pEIZ-Spy1 vector,
while our control HC11s were transfected with an empty pEIZ vector (Figure 5). pEIZ is a bacterial
DNA plasmid with insertion sites that allows for the production of specific proteins when present
inside mammalian cells (Welm et al., 2008). We then grew HC11-Spy1 and HC11 control cells in
3D Matrigel-Collagen culture with Base RPMI media supplemented with either serum (Figure 6. A
i)), serum and EGF (Figure 6.A ii) or serum and FGF (Figure 6.A iii)). EGF and FGF were chosen as
additives due to both having the ability to induce proliferation with FGF2 being a known branching
factor and EGFs shown to induce branching in certain conditions (Chen et al., 2012; Clevers,
2016). We then imaged the 3D culture cells every 24 hours for a week (Figure 5. B). We
investigated the number of organoids that were budding as opposed to simply forming spheres
and reported the percentage of budding organoids to total counter organoids per group (Figure
5). There was a main effect of Spy1 up-regulation on both the base serum (RPMIS) and EGF
supplemented media (EGF) but not in FGF supplemented media (FGF). At 24 hours only EGF
organoids showed a difference in budding between pEIZ and pEIZ-Spy1 (Figure 6.A, C). Similarly,
at 48 hours only the EGF organoids show a difference between pEIZ and pEIZ-Spy1 with the Spy1
organoids budding at significantly higher percentages (Figure 5 C). At 72 the differences between
the organoids have caught up with no significant difference between all three media conditions
(Figure 6 .C). Interestingly, there was no overall effect of Spy1 overexpression on FGF media
(Figure 6.C). The data demonstrates that Spy1 significantly enhances the budding of mammary
epithelial cells in both the presence and absence of growth factors.
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Figure 5: Schematic of organoid preparation and production. pEIZ and pEIZ-Spy1 HC11 cells were
cultured in 3:7 Matrigel Collagen mix with 3 different media conditions. RPMIS represents base
RPMI media with serum and insulin. RPMI + EGF represents RPMI media with serum and insulin
as well as EGF supplemented. RPMI + FGF represents RPMI media supplemented with serum,
insulin and FGF. The final images represent budding versus non-budding organoids.
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Figure 6: Spy1 up-regulated HC11 Organoids have higher rates of budding. A) Representative
images of organoids taken at 24h, 48h and 72h timepoints. Each image represents organoids
grown in either i) serum and EGF ii) serum and FGF iii) serum alone B) qRT-PCR analysis of HC11
cells transfected with pEIZ and pEIZ-Spy1 for Spy1 levels and corrected for GAPDH (n=3). C)
Graphical representation of the proportion of budding organoids divided by the total number of
organoids at 3 timepoints (* = p <0.05, ** = p<0.01, *** = p<0.001). Error bars represent SEM.
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MMTV-Spy1 mouse primary cell organoids have higher budding capacity
To verify the results seen using Spy1 overexpressing HC11 cells, primary mammary epithelial cells
were extracted from 8-week-old MMTV-Spy1 mice and their littermate controls and cultured in
3D Matrigel-Collagen. Organoids were allowed to grow for two weeks and total size and budding
capacity per organoid was evaluated (Figure 7A, B). We found that the MMTV-Spy1 primary cell
organoids at plating density of 2500 cells had significantly more buds formed per organoid than
their counterpart controls, while there was a non-significant difference in their sizes (Figure 7C i)).
At a plating density of 1000 cells, the MMTV-Spy1 organoids were significantly larger with no
difference in the budding capacity (Figure 7C ii)). These results led us to conclude that the MMTVSpy1 primary organoids had more growth at low density and quicker budding cues at higher cell
densities.
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Figure 7 MMTV-Spy1 primary cell organoids have more growth and branching invitro: A)
Schematic for extraction of primary cells from mice and growth in Matrigel-Collagen Media. B)
Representative images of MMTV-Spy1 primary cell extracted organoids and control cell
organoids. C) i) Representative images of 2500 density grown cells comparing size and number of
branches per organoid ii) Representative images of 1000 density grown cells comparing size and
number of branches per organoid. (* = p <0.05). Error bars represent SEM
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A

Supplementary Figure 1 Extended immunofluorescence channels for Spy1 and BrdU: A) BrdU
and Spy1 Co-stain IF with channel splits and higher resolution i) DAPI ii) GFP channel iii) Spy1 TXR
channel iv) Merge
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Discussion
Increases in lateral branching during mammary development can be a sign of both proliferation
and mis-regulation of the known branching phenotypes (Weber et al., 2017). Either mis-regulation
or hyper-proliferation can be meaningful stepping stones to tumorigenesis and can increase
susceptibility to cancer (Weber et al., 2017). Investigation into lateral branching phenotypes are
typically done to note either decrease in proliferation or precocious growth. The phenotype in
Figure 3.A showed a significant increase lateral branching. However, unlike other precocious
branching phenotypes we did not witness an increase in ductal elongation (Li et al., 2002). This
contrast suggests that Spy1 is having a specific effect on the mechanisms governing lateral side
branching but not ductal elongation, such as levels of FGF2. Similarly, the increased total epithelial
content seen in Figure 3.B is a known susceptibility marker for tumorigenesis and breast cancer
in humans (Martin and Boyd, 2008). These phenotypes support the idea that Spy1 exerts direct
effects on mammary lateral branching through increased proliferation.
When the initial budding to form a lateral side branch has occurred, any number of growth factors
can continue the elongation of the branch (Nelson et al., 2006). The EGFR pathway that
contributes to proliferation in lateral branching and within the ductal epithelium has a number of
possible agonists: EGF-1, AREG and TGF- α (Aupperlee et al., 2013; Brisken and O’Malley, 2010;
Sternlicht and Sunnarborg, 2008). In Figure 4.B we show an overall difference in AREG levels
between MMTV-Spy1 glands and the counterpart control. A significant effect of time was
observed as well likely due to the effects of Spy1 being more prominent as size and proliferative
capacity of the gland grew. Specifically, we saw a significant difference at 12-weeks and a
meaningful but non-significant difference at 6-weeks. However, we saw no difference in AREG
levels at 8-weeks likely due the previous time-point having already begun the process of
proliferation and the regulation of AREG therefore being cyclic (McBryan et al., 2008). A way to
investigate this would be to check AREG levels, using immunohistochemistry, at 4-weeks and 1618 weeks to get a better profile of its abundance in the developing gland.
This increase in AREG in the MMTV-Spy1 mice may possibly contribute to the growth of the ductal
buds leading to the phenotype seen in Figure 3. While this data shows us the plausible effects of
Spy1 on two major mammary pathways further investigation into those pathways would be
necessary. The aforementioned stromal epithelial EGFR pathway has many downstream targets
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from the EGFR receptor, including its own activation, whose abundance and activation levels
could give insight to the full effects of Spy1 on this pathway and subsequently how Spy1 causes
the increased proliferation we see in Figure 4.A. Furthermore, staining for AREG using
immunohistochemistry while useful does not differentiate between secreted and surface level
AREG. If the phenotypic effect seen is not due to total increased abundance of AREG but rather
higher level of AREG cleaved from the membrane and secreted into the stromal epithelial cleft,
then the increase in temporal AREG would be due to increased activation of ADAM17 g-coupled
protein and Spy1 would therefore have an effect on enzymatic activation rather than driving
increased expression of AREG (McBryan et al., 2008; Sternlicht and Sunnarborg, 2008).
Investigating mRNA levels of AREG and comparing them to IHC and protein levels of total
abundance would determine if more AREG is produced or more is cleaved. Spy1 could also be
affecting the TGF-β inhibitory pathway known to control the location and abundance of lateral
branching. The TGF-β inhibitory pathways downstream targets activate the Cip/Kip family p27 and
p21 both of which are known to arrest the cell cycle and halt proliferation when activated. In
literature Spy1 has been shown to cause the degradation of p27 through E3 mediated polyubiquitination and has been also shown to be less affected by p21 inhibition (Al Sorkhy et al.,
2016). It is therefore possible that Spy1 up-regulation in the gland is acting downstream of TGF-β
and negating the inhibitory aspects of the consistently activated pathway, leading to more
initiation budding events. Modulation of TGF-β signaling could lead to increased lateral branching
through decreased activation of Wnt5A and subsequent non-canonical Wnt signaling. Therefore,
investigating phosphorylation status of Ror2 receptor in the mammary epithelium would
determine if canonical Wnt activation is a component of Spy1 up-regulation. Additionally,
decreased SLIT activation could also increase the number of myoepithelial cells which has been
shown to increase the amount of lateral branching (Macias et al., 2011). However, no measured
change in the myoepithelium was seen.
The formation of organoids/3D culture from cell lines in Engelbreth-Holm-Swarm (EHS) mouse
sarcoma secreted Matrigel is a useful assay for determining growth, stemness and self-organizing
capacity (Jamieson et al., 2017; Nguyen-Ngoc et al., 2015; Ravi et al., 2015). The ability of cells to
self-organize and form structures reminiscent of their in vivo counterpart organs is one of the
many ways that the organoid assay can give insights into the cues and pathways at work in
development. Using HC11 cells transfected with pEIZ-Spy1 and pEIZ we investigated the ability of
3D cultures to form spheres and eventually budding/branching structures that mimic the
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architecture of the developing mammary gland. We were primarily interested in their ability to
form buds under minimal (serum alone RPMIS), normal (serum + EGF), and enhanced (serum +
FGF) conditions and what this could tell us about the cues Spy1 is affecting in vitro (Figure 4).
We found that Spy1 in both the minimal and normal conditions had an overall main effect (Figure
6.C) and showed significant differences at two timepoints (24 hours ,48 hour). Significant
differences between pEIZ and pEIZ Spy1 in EGF supplemented media were seen at 24 and 48 hours
but not at 72 hours (Figure 6.C i) ii)). Increased directional budding in pEIZ-Spy1 organoids in
higher proportion than simple sphere formation suggests some of the aforementioned
mechanisms. Furthermore, the increased budding proportion in the pEIZ-Spy1 organoids has
similarities to the in-vivo branching phenotype seen in the mice. If Spy1 up-regulation only
increased proliferation, then in the early timepoints (24 hours) the proportion of budding
organoids to total would likely be lower in the Spy1 upregulated HC11 cells than their counterpart
controls as more simple sphere organoids would form but would not bud at a higher rate than
control. Therefore, this would lower the proportion of budding in the pEIZ-Spy1 organoids. The
early timepoints in the serum + FGF media condition organoids show no significant difference in
the proportion of budding organoids to total between pEIZ-Spy1 and pEIZ HC11 cells (Figure 6.C
iii)). While there is a significant effect of time on the growing organoids suggesting that in the
presence of FGF2 the effects of Spy1-upregulation are silenced. This could be due to the
immediate effects of Spy1 mediated through down-stream targets of the FGFR pathway (Ornitz
and Itoh, 2015). This data demonstrates that Spy1 can enhance budding. Furthermore, this data
when paired with the previous organoids conditions suggests that Spy1 plays an important role in
budding/branching.
While this assay was insightful, its scope suffered limitations. Firstly, size could not be measured
properly between organoids as eventual outgrowth blurs the ability to image and maintaining
track of the same organoids. Secondly, with extended time measurements it was difficult to keep
track of cell death in the organoid media so any extended timing for organoid growth in-advisable
due lack of discrimination. Embedding of organoids into agarose/paraffin and sectioning for
Immunofluorescence would be a logical and necessary next step in determining if the TGF-β and
EGFR pathways are indeed affected by Spy1 up-regulation. Furthermore, investigating polarity
effects on the mammary architecture is a logical next step as cell polarity and asymmetry are
necessary components of a complex organ system (Ochoa-Espinosa and Affolter, 2012). Staining
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for golgin subfamily member A2 (Gm-130) and cytokeratin 18 (CK18) and 14 (CK14) would be
logical next steps in determining apical cell polarity and epithelial luminal concentration.
To study the effects of Spy1 on budding in primary cells we proceeded to extract mammary cells
from MMTV-Spy1- and littermate controls and grow them in Matrigel/Collagen medium according
to the schematic in Figure 7.A. These primary cells were plated at cell densities of 1000 and 2500
and allowed to grow for two weeks before imaging. We then randomly imaged several 3D
organoids per mouse. We evaluated the organoids for total area in µm2 and number of branches
per organoid. We found that at a plating density of 1000 cell per 10cm plate the MMTV-Spy1
organoids were significantly larger than their littermate controls but did not have more branches
per organoid (Figure 7.B i). However, at the 2500 cell plating density we found that the opposite
trend was true, wherein the MMTV-Spy1 organoids had significantly more branches per organoid
than their littermate controls but were no longer significantly larger (Figure 7.B ii). The growth
differences associated with plating densities may indicate Spy1’s ability to increase proliferation
leading to the formation of larger organoids at a faster rate. It is possible that the effects of Spy1
in organoid budding require a specific size before leading to branch initiation events. In the 2500
cell plating both the organoids have caught up in their size and have begun cues for branching
and cell rearrangement; at this point Spy1 could be working through the TGF-β pathway to
increase the number of budding events and through EGFR to continue elongation.
This data highlights the ability of Spy1 to increase mammary budding, mammary epithelial cell
density and proliferation in-vivo and increase budding and size in-vitro. Disruption of mammary
architecture and increased proliferation and branching are all stepping stones to tumorigenesis
and mimic mechanisms used by aggressive cancers to grow and invade (McBryan et al., 2008;
Moses and Barcellos-Hoff, 2011). When investigating Spy1 levels in tissue and tumor databases
the human protein atlas has it not to be present in normal tissues in high abundance. While may
play a role in establishment of the primary tumor after initiation and subsequent expansion; the
HPA does not show high abundance of Spy1 in breast cancer (Thul et al., 2017; Uhlen et al., 2017;
Uhlén et al., 2015)( data available from https://www.proteinatlas.org/ENSG00000163806SPDYA/tissue/breast. Conversely, in work done by Al Sorkhy et al and others has shown spy1 to
be elevated several aggressive human cancers, including breast and liver that often use
developmental pathways to advance and invade (Al Sorkhy et al., 2012; Jin et al., 2018; Ke et al.,
2009).Furthermore, Golipour et al has demonstrated spy1 being maintained at high abundance
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during post-pubertal mammary development. While the results here do not directly connect to
the data seen in breast cancer studies, they do provide correlative evidence which may link these
phenotypes to cancer development. An important step in linking the results in this work to known
cancer pathways would be to determine if indeed Spy1 and other oncogenic genes are affecting
developmental pathways examined here, in different types of breast cancer.

Future Experiments
Future experiments could include a more thorough dissection of the AREG and TGF- β pathways
using qRT, WB and IHC so that the full effect of Spy1 up-regulation could be seen. This would
therefore determine which pathways are most involved in the phenotypes and which could be
potential targets for therapy. In the mouse model, continuing the investigation to include earlier
time-points such as 4 weeks would give insight into the rise of AREG levels in mouse mammary
development as well as the initiation of proliferation both in the control mouse and in the MMTVSpy1 mouse. While differences between levels of AREG have been visualized at 12 weeks the
absence of a significant difference at 6 and 8 weeks, suggests other pathways involved in
proliferation or a staggered effect of AREG. Similarly, collecting mice at 7 weeks would increase
the range of analysis and determine when AREG levels in the control mice catch up to the MMTVSpy1. While MMTV-Spy1 mice have higher levels of proliferation and BrdU/Spy1 co-staining at 8
weeks, determining levels of proliferation at the 6- and 12-week time-points would give a more
thorough understanding of the phenotype. Our work demonstrates Spy1 can increase
proliferation in mammary development and regulated AREG levels further corroborating the work
done by Golipour et al (Golipour et al., 2008).
When bound to EGF-1 the EGFR receptor is abrogated after activation while binding to
AREG does not elicit this reaction (Kappler et al., 2015; Kerpedjieva et al., 2012). Therefore,
continued investigation into the levels of other EGFR ligands, such as EGF-1 and TGF- α, is required
to determine the effects of Spy1 on mammary developmental pathways that include EGFR.
Furthermore, AREG and EGF-1 have differing downstream targets while they both signal through
EGFR(Macdonald-Obermann and Pike, 2014). Investigation into the levels of these downstream
targets would better elucidate the full effect of these pathways and determine new possible
targets for cancer therapy. Willmarth et al has shown AREG to be a novel target for breast cancer
therapy and with further investigation from our work more targets could be determined
(Willmarth and Ethier, 2008).
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In this work we also investigated HC11 organoid budding under three specific media conditions
(see Figure 5). The HC11 3D culture could be treated with TGF- β agonists or activators for its
downstream targets, p21, p27 and Ror2 to determine if the pEIZ-Spy1 phenotype can be reduced
back to its control counterpart. Organoids could also be developed with serum-free media
conditions and different EGFR ligands introduced, such as AREG, EGF-1, TGF- α, to determine
which are more impactful in organoid budding and growth rates. Conversely, Spy1 knockout
organoids could be developed with similar media conditions to explore the possible consequences
of Spy1 loss on budding and growth. Preliminary data from other groups in our lab developing a
Crispr/Cas9 Spy1 knockout cell line show a lack of Spy1 causes differentiation in HC11 cell lines.
Therefore, investigating if these cell lines could form organoids under serum-free and growth
enriched media conditions would give further insight into Spy1’s role as a mitogen.
While not shown in this work, paraffin embedding and hematoxylin-eosin staining of the
organoids was successful. Using this technique organoids collected from the multiple media
conditions could be embedded, sectioned and evaluated using immunohistochemistry and
fluorescence. This data demonstrates Spy1’s ability to manipulate developmental pathways, such
as EGFR, in a similar manner to cancer(Moses and Barcellos-Hoff, 2011). Therefore, Spy1 levels
could be used as a potential marker of susceptibility to tumorigenesis and possibly breast cancer.
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APPENDICES
Appendix 1 Protocols
Primary Cell Isolation Protocol
DAY 1:
[A.] Prepare Reagents
1. Wash Buffer: 5% FBS/F12
25 ml FBS
5 ml AA
475 ml DMEMF12 or HamF12
500 ml
Filter sterilize.
2. 0.25% Trypsin-EDTA (InVitrogen)
3. Growth media:
250 μl 1mg/ml insulin (5μg/ml final)
50 μl 1mg/ml hydrocortisone (1μg/ml final)
25 μl 10μg/ml EGF (5ng/ml final)
250 μl 10mg/ml gentamycin (50μg/ml final)
500 μl antifungal/antibiotic
2.5 ml FBS
47 ml HamF12
50 ml
Filter sterilize.
4. Digestion Media
250 μl AA
25 mg collagenase (1mg/ml)
24.75 ml HamF12
25 ml
Filter sterilize and prepare fresh for each use.
[B.] Isolate MECs from mice
1. For the glands of 3 mice, add ~20ml of wash buffer to a 50ml conical tube.
2. Weigh tube with wash buffer and record. Place on ice.
3. Proceed with dissection, removing the #3, 4, 5 glands, removing the lymph node. Transfer
glands to
wash buffer on ice.
4. Weigh tubes with tissue, and subtract values to determine grams of tissue.
5. Chop tissue till very pasty---no clumps.
Heather LaMarca 6/07
6. Add the appropriate amount of digestion buffer to each tube: 10 ml/gram of tissue
7. Incubate tissue at 37°C on rocker, at ~50 rpm for about 14 hours. (Place tubes at a 45° angle.)
DAY 2:
8. After digestion is complete, shake digested cells vigorously to loosen cells from fat.
Transfer cells to a 15ml conical tube.
9. Spin at 1000 rpm at for 10′ using a swing bucket rotor at RT.
64

Carefully aspirate supernatant.
10. Resuspend cells in 2ml of 0.25% trypsin-EDTA by pipetting up and down.
Incubate at RT for 5′, gently inverting throughout the incubation.
Note: A large fibrous mass will ppt when trypsin is added. Also, the volume of trypsin will vary
depending on the size of the pellet. After a few minutes, the media should appear clear rather than
thick
and clumpy.
11. Neutralize trypsin with 5ml of wash buffer.
Pass cells through a 70μm filter into a 50ml conical tube. (filtration will get rid of the ppt)
12. Transfer cells back to a 15ml conical tube and bring the volume to 15ml with wash buffer.
Spin at 1000 rpm for 10′.
Carefully aspirate supernatant.
13. Continue washing to ensure that enzymatic activity is stopped (~3-4 times total).
Each time, spin at 300 × g for 5′ at RT.
14. Resuspend pellet in 3ml of growth media. Dilute cells 1:10-1:50 and count on a
hemacytometer.
Yield: ~2.5 × 106 cells per 0.5 g tissue
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